Efficacy Clinical Trial
Official title:
Endoscopic Transpapillary Gallbladder Drainage for Prevention of Biliary Complication in Surgically Unfit Patients With Both Choledocholithiasis and Cholecystolithiasis
Cholecystectomy is recommended for patients with both gallbladder (GB) and common bile duct (CBD) stones to prevent recurrent biliary complications, unless there are specific reasons for surgery is considered inappropriate. The aim of this study was to evaluate the role of transpapillary gallbladder stent placement in surgically unfit patients with both CBD stone and gallstone.
Gallstones affect 10-15% of the adult population, and 10-25% of them may develop biliary pain or complications. Patients with symptomatic gallstones often have a concomitant CBD stone in 10-20% of them. Most gallstones do not require invasive treatment due to their benign natural history, but CBD stones should be removed due to the risk of developing gallstone-related complications such as obstructive cholangitis and acute gallstone pancreatitis. CBD stones result mainly from the migration of gallstones into the bile duct, so the gold standard treatment for gallstones with CBD stones is endoscopic removal of the CBD stone followed by cholecystectomy to prevent recurrent biliary complications, such as calculous cholangitis or acute cholecystitis. However, patients who were ineligible for surgery due to high-risk conditions, including the elderly, critically ill status, and severe underlying morbidities, may not get the chance to undergo cholecystectomy. Initial nonoperative management with delayed cholecystectomy has been considered as an alternative treatment, but laparoscopic cholecystectomy reduces the rate of major complications compared with percutaneous gallbladder drainage, even in high-risk patients, and outcomes after early laparoscopic cholecystectomy in octogenarians are comparable to younger patients. Despite this evidence, there are still debates among experts for optimal treatment methods for high-risk patients for surgery with symptomatic CBD stone with gallstone, and gallbladder drainage therapy first to perform for stabilization with surgery rather than urgent cholecystectomy in real practice. Therefore, there is still an unmet need for how to prevent recurrence of CBD stones in patients with concomitant gallstones after endoscopic removal of CBD stones. Nonsurgical cholecystic drainage methods, including percutaneous transhepatic gallbladder drainage (PTGBD), endoscopic ultrasound-guided gallbladder drainage (EUS-GBD), and endoscopic transpapillary gallbladder drainage (ETGBD), have been introduced and actively used as a bridge or alternative therapy in patients at high risk for surgery. Several studies have reported the results of its feasibility and efficacy, mainly focusing on the management of patients with acute cholecystitis. However, the evidence for appropriate management considering non-surgical treatments for patients with both CBD stones and gallstones is still limited. This study evaluated the feasibility and efficacy of ETGBD for patients with both CBD stone and gallstones to prevent recurrent biliary complications in patients at high risk for surgery. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT00944268 -
Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety
|
Phase 3 | |
Completed |
NCT00504192 -
A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
|
Phase 2 | |
Recruiting |
NCT05580159 -
New Generation mRNA Booster Vaccine Against Emerging VOCs
|
Phase 3 | |
Completed |
NCT05427305 -
TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Active, not recruiting |
NCT05686161 -
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
|
Phase 3 | |
Recruiting |
NCT06284746 -
Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT04260113 -
Apatinib for Inoperable Advanced Chondrosarcoma
|
N/A | |
Recruiting |
NCT06120712 -
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04002440 -
Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight
|
N/A | |
Recruiting |
NCT02693587 -
Misodel or Angusta for Induction of Labour?
|
N/A | |
Completed |
NCT01194453 -
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05276557 -
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
|
Phase 3 | |
Recruiting |
NCT06205758 -
Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency
|
||
Recruiting |
NCT06122454 -
A Phase Ic/IIb Study to Evaluate the Efficacy,Safety and Pharmacokinetics of HST in Patients With CHB
|
Phase 1/Phase 2 | |
Recruiting |
NCT05913271 -
Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure
|
||
Recruiting |
NCT05999656 -
Human Cord Blood Mononuclear Cells in the Treatment of Refractory Diabetic Foot
|
N/A | |
Recruiting |
NCT05731258 -
Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
|
||
Recruiting |
NCT03908138 -
RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
|
Phase 4 | |
Completed |
NCT05648799 -
Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia) in Healthy Volunteers and Outpatients With COVID-19
|
N/A | |
Recruiting |
NCT03377933 -
The Effects Probiotic Has on Gastromicroecology and Combined With Quadruple Regimen for H Pylori Infection
|
N/A |